Skip to main content

Table 1 Patient characteristics

From: Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia

 

Patients (n = 24)

Age (years)

71.0 (64.8–73.3)

Prostate volume (mL)

37.3 (29.9–42.9)

PSA level (ng/mL)

1.7 (0.8–3.1)

Total IPSS

17.5 (14.0–21.0)

QOL score

4.0 (3.0–5.0)

Total OABSS

5.0 (3.0–6.0)

SHIM

7.5 (2.8–12.0)

Night-time frequency (number)

2.0 (2.0–3.0)

NPi

0.4 (0.3–0.4)

Night-time maximum voided volume (mL)

240.0 (165.0–257.5)

Maximum flow rate (mL/s)

9.7 (7.4–13.7)

Residual urine volume (mL)

52.5 (25.0–87.8)

  1. Data are presented as the median (interquartile range)
  2. PSA, prostate-specific antigen; IPSS, international prostate symptom score; QOL, quality of life; OABSS, overactive bladder symptom score; SHIM, sexual health inventory for men; NPi, Nocturnal polyuria index